Optimizing anticoagulant therapy in non-Valvular atrial fibrillation by Cassar, Andrew
the prevalence of atrial fibrillation (AF) is estimated to be around 3% of the population above 20 years of age, and increases with age, hypertension, cardiovascular 
disease, diabetes and obesity. Besides a 1.5- to 2-fold increase 
in mortality in people suffering from AF, they also have an 
increase in morbidity from heart failure and stroke. In fact, 
20-30% of all ischaemic strokes are thought to be secondary 
to AF. The CHA2DS2-VASc score is a useful tool to quantify 
the yearly risk of stroke. One should note that the risk of 
stroke is independent of whether the AF is paroxysmal, 
persistent or permanent.1
Guidelines published by the European Society of 
Cardiology2 (ESC) give a class I A indication for the 
prescription of oral anticoagulants (OACs) to males with 
a CHA2DS2-VASc score ≥ 2 and females with a score ≥ 3. 
One should also consider giving OACs to males with a 
score of 1 and females with a score of 2 (IIa B indication). 
No anticoagulants should be given to males or females with 
no additional risk factors, and anti-platelet monotherapy 
is not recommended whatever the stroke risk. A careful 
analysis of the patient’s bleeding risk should be carried out 
before prescribing these drugs. Naturally, OACs should be 
avoided in patients with active bleeding, and concomitant 
antiplatelets should only be prescribed if indication is strong. 
Vitamin K antagonists (VKAs) such as warfarin have 
been used for many years to reduce the risk of stroke and 
mortality in patients with AF. VKAs are limited by their 
narrow therapeutic interval, with patients needing frequent 
monitoring and dose adjustments. They are only effective 
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in stroke prevention when delivered with adequate time in 
therapeutic range (TTR). In the last few years Non-Vitamin 
K Oral Anticoagulants (NOACs) have made an appearance 
on the market. All NOACs (the Direct Thrombin Inhibitor 
Dabigatran, and the Factor Xa inhibitors Rivaroxaban, 
Apixiban, and Edoxaban) have the distinctive advantage over 
VKAs of having a predictable effect, and therefore no need 
for monitoring. Treatment doses are well-defined; and all are 
given as a twice-daily dose, except for Rivaroxaban, which 
is given as a once-daily dose. All four NOACs were given 
regulatory approval after each of them had been compared 
to dose-adjusted Warfarin in large randomised trials and 
were proved to be, at least, non-inferior to Warfarin in the 
prevention of stroke or embolism. Comparison between 
NOACs based on these trials is difficult as the populations 
studied were different; notably the mean CHADS2 score was 
2.1 for dabigatran (RE-LY trail3) and apixiban (ARISTOTLE 
trial4) while it was 3.5 for Rivaroxaban (ROCKET-AF trial5).
The recently updated ESC guidelines recommend NOACs 
to be prescribed instead of VKAs when this is feasible (figure 
1). Unfortunately NOACs are not yet available on the Maltese 
National Health Service, but patients might be willing to buy 
these drugs for their convenience and better safety profile. 
There are circumstances where one may actively suggest that 
a patient switches from Warfarin to NOACs. These include: 
Patients who have had a stroke or a bleed while on Warfarin, 
patients with labile INRs, and patients with low TTR. Patient 
with mechanical heart valves or mitral stenosis should be 
on VKAs and NOT given NOACs. In cases where a patient 
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with AF is unable to tolerate anti-coagulation, percutaneous 
closure of the left atrial appendage might be considered.
According to recently published data from the Global 
Anticoagulant Registry in the FIELD-Atrial Fibrillation 
(GARFIELD-AF)6 - an ongoing, prospective, observational, 
worldwide study of adults with recently diagnosed non-
valvular AF from 1215 sites in 35 countries - uptake of 
NOACs has increased steadily over the last few years. This 
has resulted in a greater proportion of patients being on 
guideline-recommended therapy. However, it is still worrying 
that slightly more than 25% of patients with CHA2DS2-VASc 
score ≥ 2 were not on any anticoagulants.
Recommendations Class Level 
When oral anticoagulation is initiated in a patient with AF who is eligible for a NOAC
(apixaban, dabigatran, edoxaban, or rivaroxaban), a NOAC is recommended in preference to
a Vitamin K antagonist. 
I A
AF patients already on treatment with a vitamin K antagonist may be considered for NOAC
treatment if TTR is not well controlled despite good adherence, or if preferred by patient without 
contra-indications to NOAC (e.g. prosthetic valve). 
IIb A
Antiplatelet monotherapy is not recommended for stroke prevention in AF patients, regardless
of stroke risk. 
III
(harm) A
Table 1. Summary of ESC 2016 anticoagulation guidelines for stroke prevention in non-valvular AF.
it is still worrying that [according to the garfield-
af registry]slightly More than 25% of patients with 
cha2ds2-vasc score  2 were not on any anticoagulants
Unfortunately, the author is not aware of any data on 
rates of anti-coagulation of AF patients in Malta. The setting 
up of a local AF registry would be an important tool to 
enable the health authorities to reduce the number of strokes 
in our country by ensuring adequate anti-coagulation 
of patients. It is strongly encouraged that all doctors 
recommend anti-coagulation, preferably with a NOAC, to 
all AF patients with one risk factor or more and no contra-
indications. 
available clinics
fully equipped clinics in the south 
of Malta, available for healthcare 
professionals.
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